Recon: Drugmakers sink after Marks’ ouster; Lilly’s drug slashes genetic heart disease risk in late-stage trial
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States